# Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms

## Metadata
**Authors:** R J Motzer, T Johnson, T K Choueiri, K C Deen, Z Xue, L N Pandite, C Carpenter, C F Xu
**Journal:** Annals of Oncology
**Date:** 2013 Oct 9
**DOI:** [10.1093/annonc/mdt394](https://doi.org/10.1093/annonc/mdt394)
**PMID:** 24107802
**PMCID:** PMC6394110
**URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394110/
**PDF:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC6394110/pdf/mdt394.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC6394110/pdf/mdt394.pdf)

## acknowledgements

We thank the investigators and their patients who made this study possible. We acknowledge Sandy Stinnett and Karen King for their contributions in data collection and discussion. Medical editorial assistance was provided by ProEd Communications, Inc.

## funding

This work was supported by GlaxoSmithKline Pharmaceuticals, Philadelphia, Pennsylvania, which also provided financial support for medical editorial assistance.

## disclosure

TJ, KCD, ZX, LNP, CC and CFX are employees of GlaxoSmithKline and own company stock. TKC is on the advisory board for GlaxoSmithKline, Pfizer, Aveo and Novartis, and holds a research grant from Pfizer. RJM has received consulting fees or honoraria from Pfizer, Genentech and AVEO Oncology; travel support from GlaxoSmithKline; and institutional grants from Pfizer, Novartis, AVEO Oncology, Genentech and GlaxoSmithKline.

## Supplementary Material

## Associated Data

*This section collects any data citations, data availability statements, or supplementary materials included in this article.*

### Supplementary Materials

### Supplementary Materials

## References

1. Motzer R, Hutson T, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369:722–731. doi: 10.1056/NEJMoa1303989.  [DOI](https://doi.org/10.1056/NEJMoa1303989) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/23964934/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Pazopanib%20versus%20sunitinib%20in%20metastatic%20renal-cell%20carcinoma&author=R%20Motzer&author=T%20Hutson&author=D%20Cella&volume=369&publication_year=2013&pages=722-731&pmid=23964934&doi=10.1056/NEJMoa1303989&)

2. Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med. 1995;333:1171–1175. doi: 10.1056/NEJM199511023331802.  [DOI](https://doi.org/10.1056/NEJM199511023331802) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/7565971/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=The%20genetic%20basis%20of%20the%20reduced%20expression%20of%20bilirubin%20UDP-glucuronosyltransferase%201%20in%20Gilbert's%20syndrome&author=PJ%20Bosma&author=JR%20Chowdhury&author=C%20Bakker&volume=333&publication_year=1995&pages=1171-1175&pmid=7565971&doi=10.1056/NEJM199511023331802&)

3. Takeuchi K, Kobayashi Y, Tamaki S, et al. Genetic polymorphisms of bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese patients with Crigler-Najjar syndrome or Gilbert's syndrome as well as in healthy Japanese subjects. J Gastroenterol Hepatol. 2004;19:1023–1028. doi: 10.1111/j.1440-1746.2004.03370.x.  [DOI](https://doi.org/10.1111/j.1440-1746.2004.03370.x) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/15304120/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Gastroenterol%20Hepatol&title=Genetic%20polymorphisms%20of%20bilirubin%20uridine%20diphosphate-glucuronosyltransferase%20gene%20in%20Japanese%20patients%20with%20Crigler-Najjar%20syndrome%20or%20Gilbert's%20syndrome%20as%20well%20as%20in%20healthy%20Japanese%20subjects&author=K%20Takeuchi&author=Y%20Kobayashi&author=S%20Tamaki&volume=19&publication_year=2004&pages=1023-1028&pmid=15304120&doi=10.1111/j.1440-1746.2004.03370.x&)

4. Xu CF, Reck BH, Xue Z, et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br J Cancer. 2010;102:1371–1377. doi: 10.1038/sj.bjc.6605653.  [DOI](https://doi.org/10.1038/sj.bjc.6605653) | [PMC free article](/articles/PMC2865761/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/20389299/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Br%20J%20Cancer&title=Pazopanib-induced%20hyperbilirubinemia%20is%20associated%20with%20Gilbert's%20syndrome%20UGT1A1%20polymorphism&author=CF%20Xu&author=BH%20Reck&author=Z%20Xue&volume=102&publication_year=2010&pages=1371-1377&pmid=20389299&doi=10.1038/sj.bjc.6605653&)

5. Fujita K, Sugiyama M, Akiyama Y, et al. Inhibition of UGT1A1-mediated SN-38 glucuronidation by small molecule of tyrosine kinase inhibitors. Clin Pharmacol Thera. 2010;87:S80.  [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin%20Pharmacol%20Thera&title=Inhibition%20of%20UGT1A1-mediated%20SN-38%20glucuronidation%20by%20small%20molecule%20of%20tyrosine%20kinase%20inhibitors&author=K%20Fujita&author=M%20Sugiyama&author=Y%20Akiyama&volume=87&publication_year=2010&pages=S80&)
